Talabostat mesylate is a potent and selective DPP4 inhibitor (IC50: 0.18 nM) that also targets fibroblast activation protein. It has been studied in preclinical cancer research for its potential to modulate the tumor microenvironment and stimulate hematopoiesis via G-CSF induction.